Enlivex Historical Income Statement

ENLV Stock

USD 1.00 0.01 0.99%

Historical analysis of Enlivex Therapeutics income statement accounts such as Research Development of 23.2 M or Cost Of Revenue of 713.9 K can show how well Enlivex Therapeutics performed in making a profits. Evaluating Enlivex Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Enlivex Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Enlivex Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Enlivex Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.

About Enlivex Income Statement Analysis

Enlivex Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Enlivex Therapeutics shareholders. The income statement also shows Enlivex investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Enlivex Therapeutics Income Statement Chart

At this time, Enlivex Therapeutics' Interest Income is fairly stable compared to the past year. Reconciled Depreciation is likely to climb to about 1 M in 2025, whereas Cost Of Revenue is likely to drop slightly above 713.9 K in 2025.

Research Development Cost Of Revenue Selling General Administrative Other Operating Expenses

Cost Of Revenue

Cost of Revenue is found on Enlivex Therapeutics income statement and represents the costs associated with goods and services Enlivex Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Enlivex Therapeutics. It is also known as Enlivex Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Enlivex Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Enlivex Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.At this time, Enlivex Therapeutics' Interest Income is fairly stable compared to the past year. Reconciled Depreciation is likely to climb to about 1 M in 2025, whereas Cost Of Revenue is likely to drop slightly above 713.9 K in 2025.

	2022	2023	2024	2025 (projected)
Cost Of Revenue	777K	835K	751.5K	713.9K
Research Development	18.7M	19.2M	22.1M	23.2M

Cost Of Revenue Research Development

Enlivex Therapeutics income statement Correlations

	Interest Expense	Research Development	Cost Of Revenue	Selling General Administrative	Gross Profit	Income Tax Expense	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Depreciation And Amortization	Selling And Marketing Expenses	Tax Provision	Net Interest Income	Interest Income	Net Income From Continuing Ops	Reconciled Depreciation
Interest Expense		0.34	-0.06	0.04	-0.12	0.71	0.28	-0.36	-0.37	-0.37	0.28	-0.48	-0.67	-0.64	0.26	0.25	-0.25	0.14	0.14	-0.54	0.33
Research Development	0.34		-0.04	0.24	-0.16	0.62	0.97	-0.94	-0.94	-0.93	0.97	-0.92	-0.07	-0.86	0.75	0.71	-0.58	0.85	0.89	-0.74	0.95
Cost Of Revenue	-0.06	-0.04		0.94	0.98	-0.1	-0.27	0.29	0.3	0.29	-0.27	0.28	0.01	0.26	-0.2	-0.23	0.28	-0.13	-0.13	0.0	-0.17
Selling General Administrative	0.04	0.24	0.94		0.89	0.03	0.03	-0.02	-0.01	-0.02	0.03	-0.02	0.0	-0.02	-0.03	-0.09	0.15	0.05	0.06	-0.19	0.05
Gross Profit	-0.12	-0.16	0.98	0.89		-0.16	-0.37	0.39	0.4	0.39	-0.37	0.38	-0.02	0.34	-0.3	-0.28	0.32	-0.23	-0.24	0.11	-0.28
Income Tax Expense	0.71	0.62	-0.1	0.03	-0.16		0.58	-0.57	-0.57	-0.57	0.58	-0.69	-0.78	-0.82	0.51	0.47	-0.4	0.7	0.66	-0.7	0.63
Other Operating Expenses	0.28	0.97	-0.27	0.03	-0.37	0.58		-0.98	-0.97	-0.97	1.0	-0.95	-0.04	-0.88	0.74	0.69	-0.59	0.84	0.88	-0.69	0.92
Operating Income	-0.36	-0.94	0.29	-0.02	0.39	-0.57	-0.98		1.0	1.0	-0.98	0.98	0.07	0.91	-0.71	-0.67	0.59	-0.76	-0.79	0.7	-0.88
Ebit	-0.37	-0.94	0.3	-0.01	0.4	-0.57	-0.97	1.0		1.0	-0.97	0.98	0.07	0.91	-0.71	-0.67	0.6	-0.75	-0.79	0.69	-0.88
Ebitda	-0.37	-0.93	0.29	-0.02	0.39	-0.57	-0.97	1.0	1.0		-0.97	0.98	0.07	0.91	-0.69	-0.66	0.58	-0.75	-0.78	0.69	-0.87
Total Operating Expenses	0.28	0.97	-0.27	0.03	-0.37	0.58	1.0	-0.98	-0.97	-0.97		-0.95	-0.04	-0.88	0.74	0.69	-0.59	0.84	0.88	-0.69	0.92
Income Before Tax	-0.48	-0.92	0.28	-0.02	0.38	-0.69	-0.95	0.98	0.98	0.98	-0.95		0.25	0.97	-0.71	-0.65	0.58	-0.77	-0.79	0.74	-0.87
Total Other Income Expense Net	-0.67	-0.07	0.01	0.0	-0.02	-0.78	-0.04	0.07	0.07	0.07	-0.04	0.25		0.46	-0.12	-0.04	0.05	-0.19	-0.11	0.36	-0.07
Net Income	-0.64	-0.86	0.26	-0.02	0.34	-0.82	-0.88	0.91	0.91	0.91	-0.88	0.97	0.46		-0.67	-0.61	0.55	-0.72	-0.73	0.77	-0.81
Depreciation And Amortization	0.26	0.75	-0.2	-0.03	-0.3	0.51	0.74	-0.71	-0.71	-0.69	0.74	-0.71	-0.12	-0.67		0.84	-0.76	0.72	0.74	-0.45	0.81
Selling And Marketing Expenses	0.25	0.71	-0.23	-0.09	-0.28	0.47	0.69	-0.67	-0.67	-0.66	0.69	-0.65	-0.04	-0.61	0.84		-0.9	0.63	0.67	-0.29	0.8
Tax Provision	-0.25	-0.58	0.28	0.15	0.32	-0.4	-0.59	0.59	0.6	0.58	-0.59	0.58	0.05	0.55	-0.76	-0.9		-0.51	-0.53	0.09	-0.68
Net Interest Income	0.14	0.85	-0.13	0.05	-0.23	0.7	0.84	-0.76	-0.75	-0.75	0.84	-0.77	-0.19	-0.72	0.72	0.63	-0.51		0.99	-0.69	0.9
Interest Income	0.14	0.89	-0.13	0.06	-0.24	0.66	0.88	-0.79	-0.79	-0.78	0.88	-0.79	-0.11	-0.73	0.74	0.67	-0.53	0.99		-0.7	0.93
Net Income From Continuing Ops	-0.54	-0.74	0.0	-0.19	0.11	-0.7	-0.69	0.7	0.69	0.69	-0.69	0.74	0.36	0.77	-0.45	-0.29	0.09	-0.69	-0.7		-0.72
Reconciled Depreciation	0.33	0.95	-0.17	0.05	-0.28	0.63	0.92	-0.88	-0.88	-0.87	0.92	-0.87	-0.07	-0.81	0.81	0.8	-0.68	0.9	0.93	-0.72

Click cells to compare fundamentals

Enlivex Therapeutics Account Relationship Matchups

Enlivex Therapeutics income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Interest Expense	6K	328K	5.3M	14K	16.1K	15.3K
Research Development	6.1M	12.9M	18.7M	19.2M	22.1M	23.2M
Cost Of Revenue	286K	546K	777K	835K	751.5K	713.9K
Selling General Administrative	3.6M	6.2M	6.7M	6.1M	5.5M	8.1M
Gross Profit	2.0M	(546K)	(777K)	(835K)	(751.5K)	(713.9K)
Income Tax Expense	2.0M	(4.8M)	11.3M	4.2M	4.9M	5.1M
Other Operating Expenses	9.8M	19.3M	25.8M	29.4M	33.8M	35.5M
Operating Income	(9.8M)	(19.3M)	(25.8M)	(29.4M)	(26.5M)	(25.1M)
Ebit	(9.8M)	(19.3M)	(25.8M)	(29.1M)	(26.1M)	(24.8M)
Ebitda	(9.5M)	(18.7M)	(25.0M)	(28.2M)	(25.4M)	(24.1M)
Total Operating Expenses	9.8M	19.3M	25.8M	29.4M	33.8M	35.5M
Income Before Tax	(11.8M)	(14.5M)	(31.1M)	(29.1M)	(26.2M)	(24.9M)
Total Other Income Expense Net	(2.0M)	4.8M	(5.3M)	327K	294.3K	309.0K
Net Income	(13.9M)	(9.6M)	(42.4M)	(29.1M)	(26.2M)	(24.9M)
Depreciation And Amortization	286K	546K	777K	835K	960.3K	1.0M
Net Interest Income	219K	(208K)	821K	1.6M	1.8M	1.9M
Interest Income	225K	120K	835K	1.6M	1.8M	1.9M
Net Income From Continuing Ops	(11.8M)	(14.5M)	(31.1M)	(27.2M)	(24.4M)	(23.2M)
Net Income Applicable To Common Shares	(9.6M)	(11.8M)	(14.5M)	(31.1M)	(28.0M)	(26.6M)
Reconciled Depreciation	286K	546K	777K	856K	984.4K	1.0M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Enlivex Stock Analysis

When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Enlivex Historical Income Statement

About Enlivex Income Statement Analysis

Enlivex Therapeutics Income Statement Chart

Cost Of Revenue

Other Operating Expenses

Enlivex Therapeutics income statement Correlations

Enlivex Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Enlivex Therapeutics income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Enlivex Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Interest Expense	Total Revenue
Research Development	Cost Of Revenue
Selling General Administrative	Gross Profit
Income Tax Expense	Other Operating Expenses
Operating Income	Ebit
Ebitda	Total Operating Expenses
Income Before Tax	Total Other Income Expense Net
Net Income	Depreciation And Amortization
Selling And Marketing Expenses	Tax Provision
Net Interest Income	Interest Income
Net Income From Continuing Ops	Net Income Applicable To Common Shares
Reconciled Depreciation

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Interest Income	+ 0.99	Net Interest Income
Gross Profit	+ 0.98	Cost Of Revenue

Total Operating Expenses	- 0.98	Operating Income
Operating Income	- 0.98	Other Operating Expenses
Total Operating Expenses	- 0.97	Ebitda
Total Operating Expenses	- 0.97	Ebit
Ebitda	- 0.97	Other Operating Expenses
Ebit	- 0.97	Other Operating Expenses